Next Article in Journal
Effects of Assault Type on Cognitive Behaviour Therapy for Coexisting Depression and Alcohol Misuse
Previous Article in Journal
Evidence of Oxidative Stress and Secondary Mitochondrial Dysfunction in Metabolic and Non-Metabolic Disorders
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessReview
J. Clin. Med. 2017, 6(7), 70;

Omega-3 Polyunsaturated Fatty Acids for the Treatment of IgA Nephropathy

Apheresis and Dialysis Center, Keio Univerisity School of Medicine, Tokyo 1608582, Japan
Academic Editors: Fiorella Gurrieri and Eugenio Sangiorgi
Received: 17 April 2017 / Revised: 7 July 2017 / Accepted: 12 July 2017 / Published: 19 July 2017
(This article belongs to the Special Issue Molecular Biology of IgA Nephropathy)
Full-Text   |   PDF [581 KB, uploaded 19 July 2017]   |  


IgA nephropathy is a common disease that causes end-stage renal failure and requires renal replacement therapy. The main purpose of therapeutic intervention in this disease is not limited to improvement of prognosis and prevention of transition to end-stage renal failure, but also prevention of the occurrence of cardiovascular lesions, which increases risk in patients with chronic kidney disease. Steroids and immunosuppressants have been widely used as remission induction therapies; however, the balance between their therapeutic benefits and detrimental side-effects are controversial. In this regard, it is critical to identify alternative therapies which would provide holistic life-long benefits. Currently, the potential of ω-3 fatty acids as anti-inflammatory and inflammation-convergent drugs—especially the remarkable progress of the multifunctional ω-3 polyunsaturated fatty acids (PUFAs)—has garnered attention. In this section, we outline the background and current status of ω-3 PUFA-based treatment in IgA nephropathy. View Full-Text
Keywords: ω-3 PUFAs; EPA; DHA; IgA nephropathy; aspirin ω-3 PUFAs; EPA; DHA; IgA nephropathy; aspirin

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Hirahashi, J. Omega-3 Polyunsaturated Fatty Acids for the Treatment of IgA Nephropathy. J. Clin. Med. 2017, 6, 70.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top